Experimental Study of the Labeling Method and Inhibitive Effects on Non-Hodgkin’s B-cell Lymphoma Cells of ~(131)I-Rituximab

Objective To investigate the feasibility of targeted on non-Hodgkin Lymphoma with 131I-Rituximab.Methods Rituximab is a kind of monoclonal antibody to NHL.The 131I-Rituximab was prepared by Tosylchloramide Sodium labeling way.The CCK-8 method was used to determine the inhibitive effect of the 131I-Rituximab.The control group were 131I、Rituximab.Results The labeling yield of 131I-Rituximab was above 92%. The results of CCK-8 method showed that the inhibitive effect of 131I-Rituximab was much stronger than 131I and Rituximab (P0.01).Conclusion 131I-Rituximab provides a promising may of targeted therapy on non-Hodgkin's B-cell lymphoma .